Robbins LLP said it is investigating allegations that Unicycive Therapeutics failed to correct deficiencies at a vendor’s manufacturing facility. The report introduces regulatory/quality risk over the company’s supply chain controls, but no financial metrics or guidance changes were provided.
Robbins LLP said it is investigating allegations that Unicycive Therapeutics failed to correct deficiencies at a vendor’s manufacturing facility. The report introduces regulatory/quality risk over the company’s supply chain controls, but no financial metrics or guidance changes were provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
